A Phase 1 Study of JNJ-80038114, a T-Cell Redirecting Agent Targeting Prostate Specific Membrane Antigen (PSMA), for Advanced Stage Prostate Cancer
Latest Information Update: 02 Oct 2024
At a glance
- Drugs JNJ-80038114 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Janssen Research & Development
Most Recent Events
- 03 May 2024 Status changed from active, no longer recruiting to completed.
- 24 Apr 2024 Planned End Date changed from 21 Mar 2025 to 29 Sep 2024.
- 24 Apr 2024 Status changed from recruiting to active, no longer recruiting.